Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Options

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Dec 10, 2023 7:53am

182 Views

Post# 35776724

RE:RE:RE:RE:RE:Options

Indeed. The most important & exciting 6 to 9 months failed to come to fruition. The aforementioned two individuals have only to step up this week to at least temporarily address investor concerns. Become shareholders. I'm sure Matt's apologists are readying their excuses, but there really are none. GLTA.

<< Previous

Bullboard Posts

Next >>

10 common investing mistakes to avoid